The formation of MAC and/or the release of C5a from unregulated complement activity causes localized damage of the post-synaptic membrane of the NMJ, which makes terminal complement inhibition a potentially useful treatment approach for illnesses such as MG [31]. The gene discussed is C5; the disease is myasthenia gravis.